Full-Time

Associate Director/Director

Process Development

Posted on 11/1/2024

Korro Bio

Korro Bio

51-200 employees

Develops RNA-based therapies for diseases

Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Hybrid position at 60 first st, Cambridge, MA 02141.

Category
Genomics
Public Health
Biology & Biotech
Requirements
  • PhD in Chemical Engineering, Biochemistry, Biotechnology, or a related field; or equivalent combination of education and experience.
  • 6+ years hands-on experience in oligonucleotide manufacturing and process characterizations (DoE studies) and scale up activities.
  • Proven track record in leading process development from preclinical to clinical phases, including technology transfer to manufacturing.
  • Experience in DP manufacturing process development and understanding the DP regulatory requirements is good to have.
  • Experience working with CMOs and managing external collaborations.
  • Knowledge of current Good Manufacturing Practices (cGMP) and regulatory guidelines (FDA, EMA) for biologics.
  • Strong leadership skills with demonstrated ability to manage and mentor teams.
  • Excellent problem-solving, communication, and organizational skills.
  • Ability to thrive in a fast-paced, dynamic environment with changing priorities.
Responsibilities
  • Lead the development and optimization of upstream and downstream manufacturing processes for RNA-based therapies.
  • Oversee process characterization, scale-up activities, and tech transfer to internal or external manufacturing partners.
  • Develop and implement strategies for process development to support early-stage clinical programs and eventual commercialization.
  • Collaborate cross-functionally with R&D, quality assurance, regulatory affairs, and external CMOs (Contract Manufacturing Organizations) to align process development goals with clinical and regulatory requirements.
  • Ensure processes comply with relevant regulatory requirements (e.g., FDA, EMA) and cGMP standards.
  • Contribute to CMC strategy, including risk assessment, contingency planning, and troubleshooting during process scale-up or tech transfer.
  • Lead, mentor, and develop a high-performing team of process development scientists and engineers.
  • Manage project timelines, budgets, and resources to meet corporate milestones.
  • Author and review key regulatory documents (IND, IMPD, NDA, etc.) in partnership with the regulatory team.

Korro Bio develops RNA-based therapies aimed at treating serious diseases that lack effective treatments. Their approach utilizes RNA editing, which allows for precise changes at the RNA level to modify protein function, offering a more accurate alternative to traditional gene editing methods. This company stands out from competitors by focusing on single base edits, which are considered less risky. Korro Bio's goal is to advance medical treatments through extensive research and development, ultimately bringing new therapies to market either independently or through partnerships with larger pharmaceutical companies. They aim to provide hope to patients in need and collaborate with academic institutions to enhance their scientific research.

Company Stage

IPO

Total Funding

$383.7M

Headquarters

Cambridge, Massachusetts

Founded

2019

Growth & Insights
Headcount

6 month growth

1%

1 year growth

0%

2 year growth

8%
Simplify Jobs

Simplify's Take

What believers are saying

  • Korro Bio raised $70M for clinical trials and growth in April 2024.
  • Partnership with Novo Nordisk targets cardiometabolic diseases like obesity and diabetes.
  • Recent FDA approvals support RNA-based treatments, benefiting Korro Bio's pipeline.

What critics are saying

  • Potential competition from RNA editing companies like Beam Therapeutics.
  • Merger with Frequency Therapeutics may lead to integration challenges.
  • Stock price surge could lead to market volatility and investor scrutiny.

What makes Korro Bio unique

  • Korro Bio uses RNA editing for precise protein function modifications.
  • Their platform targets diseases with limited or no current treatment options.
  • Korro Bio's RNA editing is considered superior to traditional gene editing.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE